

**Performance in Delivering Research (PID) Q4 2016/17**

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
15/SC/0676	ANNOUNCE - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma	Number Agreed	2	Date Agreed	30/08/2019	2	27/05/2016	Recruitment Finished	Target Achieved
13/WM/0421	TARGOVAX: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas	Number Agreed	10	Date Agreed	01/04/2016	12	02/05/2016	Recruitment Finished	Target Achieved
15/EM/0305	CANC - 4278 - GTx-024 in Advanced, AR+ TNBC: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)	Number Agreed	2	Date Agreed	02/09/2016	0	12/09/2016	Withdrawn By Sponsor	Unable to achieve recruitment target as Sponsor withdrew the study in the UK due to lack of recruitment.
15/EE/0385	NEPTUNE Lung: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non	Number Agreed	4	Date Agreed	24/09/2018	5	07/09/2016	Withdrawn By Host	Target Achieved

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/LO/0135	BAYER 15396: A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve subject	Number Agreed	6	Date Agreed	30/07/2021	5	22/08/2016	Recruitment Finished	Study closed as recruitment target achieved nationally.
15/LO/0448	RAINFALL: NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	12	Date Agreed	31/12/2018	8	18/08/2016	Recruitment Finished	Study closed earlier than planned as recruitment target achieved nationally.
15/EE/0013	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with o	Number Agreed	4	Date Agreed	27/05/2016	8	13/07/2016	Recruitment Finished	Target Achieved
13/LO/1277	SPARTAN - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Number Agreed	6	Date Agreed	08/11/2018	10	21/06/2016	Recruitment Finished	Target Achieved
15/LO/0691	Checkmate - 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen fo	Number Agreed	4	Date Agreed	30/05/2016	23	31/05/2016	Recruitment Finished	Target Achieved

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
14/LO/1426	NCRN - 2960 - Unresected Stage IIIB - IVM1a Melanoma Treated with Talimogene Laherparepvec	Number Agreed	3	Date Agreed	30/11/2016	5	09/06/2016	Recruitment Finished	Target achieved
15/LO/0236	A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	Number Agreed	6	Date Agreed	31/03/2018	4	13/06/2016	Recruitment Finished	8 patients screened, 2 patients declined due to requirement of fresh biopsy, 2 patients were ineligible and 4 patients were recruited. Study involved complex screening procedures and also has a short screening window.
15/NW/0690	MK-3475-054: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group	Number Agreed	3	Date Agreed	01/03/2024	2	11/10/2016	Recruitment Finished	5 patients consented, 3 were ineligible following screening tests and 2 were recruited.
15/LO/0897	WO29637 - MPDL3280A in renal cell: A phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma	Number Agreed	6	Date Agreed	21/10/2016	13	12/10/2016	Recruitment Finished	Target achieved
14/LO/1151	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and A	Number Agreed	15	Date Agreed	31/12/2016	14	28/11/2016	Recruitment Finished	Target Achieved

Research Ethics Committee Reference Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
15/NW/0671	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma	Number Agreed	5	Date Agreed	31/03/2018	2	21/12/2016	Recruitment Finished	Rare cancer group with unwell patients. Study was difficult to recruit to in this population. 23 screened in total.
16/LO/085	A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Number Agreed	3	Date Agreed	06/03/2017	4	23/01/2017	Recruitment Finished	Target Achieved
15/NW/0713	A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women	Number Agreed	2	Date Agreed	31/10/2018	3	17/02/2017	Recruitment Finished	Target Achieved
15/EM/0546	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL)	Number Agreed	4	Date Agreed	10/02/2018	2	20/03/2017	Withdrawn By Sponsor	Rare cancer group, Sponsor closed study recruitment earlier than planned.
14/EM/0089	A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.	Number Agreed	2	Date Agreed	13/06/2017	2	29/03/2017	Recruitment Finished	Target Achieved